REGULATORY INTELLIGENCE·Recall
Gilead Sciences Initiates Class I Recall of 105,000 Veklury (Remdesivir) Vials Due to Glass Particulates
Gilead Sciences, Inc. has initiated a Class I recall of 105,000 vials of Veklury (remdesivir) for injection due to glass particulate matter. This voluntary, nationwide U.S. recall, terminated on July 29, 2025, signals significant supply chain disruption and heightened regulatory scrutiny on sterile injectable products, demanding immediate action from procurement and quality assurance teams.
90-Day Activity